Replies to post #228380 on Biotech Values

[DewDiligence]

Re: PD-(L)1 agents for HBV

…I don't think this will be enough and combinations are needed…

No question about that (IMO), but the salient point is that no one will want to administer PD-(L)1 agents indefinitely the way nukes are currently used to treat chronic HBV. Hence, unless PD-(L)1 agents can be a component of some kind of curative regimen, they won’t have any commercial role to play in HBV.

Thanks for the references.